Caremark Rx — Advancepcs — Merger or Acquisition (October 2003)
28 slides from Caremark Rx's merger presentation, Oct 29, 2003
Slide 1: Forward Looking Statements
Forward Looking Statements Certain statements contained in this presentation constitute forward- looking statements contemplated under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding benefits of the proposed merger and expected syne
Slide 2: Agenda
Agenda ai +: Introduction + Merger Overview > Transaction Terms > Timetable Update > Combination Benefits + AdvancePCS Recent Financial Performance + Caremark Rx Recent Financial Performance - Q&A
Slide 3: Merger Overview
Merger Overview
Slide 4: Key Transaction Terms
Key Transaction Terms Per share consideration: Value equivalent to 2.15 Caremark shares per AdvancePCS share Consideration mix: 90% stock / 10% cash Transaction structure: Tax-free reorganization, excluding cash component Conditions to closing: * Caremark and AdvancePCS stockholder approval * Custom
Slide 5: Merger Timing Update
Merger Timing Update September 2, 2003: Caremark/AdvancePCS Merger Announced September 10, 2003: Initial HSR Filing Made + October 6, 2003: Joint Proxy/Form S-4 Filed with SEC « October 10, 2003: Caremark and AdvancePCS receive requests for additional information from FTC
Slide 6: Strategic Benefits
Strategic Benefits ai + Enhanced provider of health management solutions + Highly complementary businesses » Increased customer diversity > Recognized expertise in mail service and retail programs. > Broader specialty programs » Comprehensive disease management solutions AdvancePCs + Expertise in dr
Slide 7: Complementary Customer Mix
Complementary Customer Mix Caremark will apply best practices from both organizations to focus on the particular needs of clients within each client segment Caremark Employer! Government AdvancePCS* Employer! Government Health Plans 1 Excludes AdvancePCS cash oard and rebate ublty scripts Note: Base
Slide 8: Enhanced Customer Value
Enhanced Customer Value Expanded size and scope expected to provide enhanced value for clients + Caremark will be in a position to offer enhanced value for clients as a large, diversified, independent PBM + Combined companiae rocessed over 600 million prescriptions in the twelve months ended Septemb
Slide 9: Broader Choice and Convenience for Customers
Broader Choice and Convenience for Customers Hessquates —— @ Speaaty Pharmacy | Sera O cect A. calcente | Nota: Blue symbol represents AdvanceP CS facility Red symbol represents Caremark facility 10 €3 AdvancePCs
Slide 10: Premier Specialty Programs
Premier Specialty Programs a cs 2 AdvorcePCS + 25 years of experience + TheraCom key therapies: + Key therapies: > Pulmonary hypertension > Hemophilia > Gaucher disease > Growth Hormone > Fabry disease > Multiple Sclerosis > Hurler’s syndrome > Hepatitis C > Multiple Sclerosis > RSV EE + Expanded sp
Slide 11: Complementary Disease Management
Complementary Disease Management 4 Con RE Ader? + CarePatterns Programs: + Accordant Health: > Asthma* > Seizures” > Dermatomyositis” > Pediatric Asthma > RAY > Cystic fibrosis” > CAD* > Parkinson’s* > Gaucher* > CHF* > Scleroderma* > Multiple Sclerosis* > COPD > Hemophilia® > Polymyositis* > Diabet
Slide 12: Enhanced Mail Order Opportunity
Enhanced Mail Order Opportunity ail + Transaction expected to expand opportunities for further penetration of mail order services > Increases safety, compliance and convenience > Provides savings for clients and members ‘ent technology in each company’s state of the art mail Mail Penetration Rates!
Slide 13: Overview of Expected Financial Benefits
Overview of Expected Financial Benefits + Expected to be accretive to Caremark Rx EPS in the near term * $125 million in expected synergies in first year following closing with a majority coming through purchasing efficiencies + The combined company is anticipated to have a strong balance sheet with
Slide 14: Transaction Summary
Transaction Summary + Enhanced provider of health management solutions + Highly complementary businesses > Increased customer diversity with over 600 million prescriptions in the twelve months ended September 30, 2003 > Expanded distribution strengths > Broader specialty pharmaceutical and disease m
Slide 15: Link
Link to searchable text of slide shown above
Slide 16: AdvancePCS Strong Financial Performance
AdvancePCS Strong Financial Performance Three Months Ended September 30 ail ($ Millions) 2003 2002 % Chg Earnings $ 613 $ 42.2 21.6% EPS $ 0.52 $ 0.43 20.9% EBITDA $ 106.6 $ 91.0 17.1% EBITDA/Adjusted Claim $ 0.81 $ 0.69 17.4% Excluding Merger-related Charges*: Earnings $ 63.3 $ 42.2 26.3% EPS $ 0.5
Slide 17: AdvancePCS EBITDA & EBITDA per Claim
AdvancePCS y EBITDA & EBITDA per Claim* $120 $1.40 $1.20 $1.00 = J a : cs rs gas 5 S = : $oe0 2 Ey $0.40 $0.20 $0.00 3001 4001 1002 2002 3002 4002 1003 2003 3003 4003 1004 2004 sm EBITDA EBITDA per Claim* EBITDA per olsim bacad on adjusted claire: pharmacy’network claims plue mail claim multiplied b
Slide 18: AdvancePCS Cash Flow from Operations
AdvancePCS Cash Flow from Operations (S millions) $269 $143 pied $92 gs0 «$82 | i | _ a | = $50 $15 $o += 1998 1999 2000 2001 2002 2003 YTD 2004 _ Capital Expenditures mFree Cash Flow Source: As reported forfical years ended March 31 and periad ended September 0, 2003 19
Slide 19: AdvancePCS Debt and Debt/EBITDA
AdvancePCS Debt and Debt/EBITDA* 4.50 4.00 $800 3.50 3.00 $600 aa $400 po 1.50 $200 ‘hg 0.50 $0 0.00 3001 4001 Q102 2002 3002 4002 1003 2003 3003 4003 1004 2004 = = 3 2 a Debt to EBITDA. [Debt -- Debt to EBITDA* + EBITDA based on quarterly reported dats annualized (current period multiplied by four)
Slide 20: AdvancePCS FY2004 Guidance
AdvancePCS FY2004 Guidance Estimated EPS $2.13 - $2.17 EPS growth based on guidance 25% - 27%
Slide 21: Caremark Rx Financial Overview
Caremark Rx Financial Overview & * Quarter Ended September 30, 2003 a ve
Slide 22: Caremark Strong Financial Performance
Caremark Strong Financial Performance =. Three Months Ended September 30 ze ($Millions) 2003 2002 % Chq Net Revenues $2,256.8 $1,713.4 31.7% EBITDA $150.5 $108.1 39.2% Income-Cont Operations $76.8 $53.2 44.5% EPS — Cont Oper (40% T.R.) $.29 $.20 45.0% Operating Cash Flow $164.9 $121.0 36.3% EBITDA/A
Slide 23: Consistent EBITDA Growth
ix «#2 | .* Consistent EBITDA Growth EBITDA & EBITDA per Claim* $160 $4.00 $3.50 are ‘| $3.00 $2.50 2.00 $1.50 1.00 90.50 $0.00 EBITDA per Clam* EBITDA e 8 € 8 2 3 Ss | Sy ae | @101 9201 Q301 Qa at02 O%2 Q302 Qa O13 9203 9303 == EBITDA EBITDA per Claim*
Slide 24: Link
Link to searchable text of slide shown above
Slide 25: Strong Cash Flow has Reduced Leverage
Strong Cash Flow has Reduced Leverage Caremark Balance Sheet is Flexible [zaNetDebt — — Net Debtto EBITDA 12.00 1000 & = ‘ oO = ae |” 8.00 = ° = $1,100 600 = a 3 Q $800 4 400 3 ~ = $500 | 200 2 i ) $200 0.00 1998 1999 2000 2001 2002 9/30/2003
Slide 26: Caremark Q4 2003 Guidance
Caremark @42003 Guidance Revenue Growth: Approx 30% EPS: $.31* *Tax Rate = 40%. Excludes AdvancePCs integration planning expenses and corporate relocation expenses of approximately $4 million
Slide 27: Link
Link to searchable text of slide shown above
Slide 28: Searchable text section of graphics shown above
Searchable text section of graphics shown above Forw ard Looking Statements Certain statements contained in this presentation constitute forward-looking statements contemplated under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding b